文献速递乳腺癌放疗放疗物理与技术

乳腺放疗省略内乳淋巴结覆盖对肌肉骨骼剂量学的影响

Impact of excluding internal mammary node coverage on musculoskeletal dosimetry in breast radiotherapy.
PubMed 文献 · Clin Transl Radiat Oncol · 2025-11-15

该回顾性剂量学研究纳入30例接受保乳术及区域淋巴结放疗的乳腺癌患者,对比包含与不包含内乳淋巴结(IMN)覆盖的两套放疗计划的肌肉骨骼剂量学差异。结果显示省略IMN覆盖可显著降低后侧、后外侧等肌群的平均剂量,最大绝对降幅见于大圆肌(340 cGy)和肩胛下肌(320 cGy)。

要点

  • 省略IMN覆盖显著降低后侧肌群平均剂量,大圆肌降340 cGy。
  • 胸小肌V40差异为12%,胸大肌V40差异为10%。
  • 年轻、乳房较大、瘤腔较大及非中央肿瘤者剂量差异更大。

核心结论

  • 省略IMN覆盖可显著降低颈部、胸壁和肩部肌肉骨骼结构所受剂量,尤其是后侧肌群。

研究设计与样本

  • 单中心回顾性研究,纳入2022年1月1日至2023年11月30日接受保乳术及淋巴结取样后辅助大分割全乳和区域淋巴结放疗(4005 cGy/15次)的乳腺癌患者30例。

主要发现

  • 省略IMN覆盖后,后侧、后外侧、外侧、前侧及前外侧-后侧区域肌群的平均剂量显著降低。
  • 平均剂量绝对降幅最大的是大圆肌(340 cGy)、肩胛下肌(320 cGy)、前锯肌(241 cGy)、背阔肌(232 cGy)、胸壁(209 cGy)和胸小肌(37 cGy)。
  • 胸小肌V40差异为12%,胸大肌V40差异为10%,肩胛下肌和大圆肌V15差异均为8%。
  • 与剂量差异较大相关的患者因素包括年轻年龄、较大乳房尺寸、较大肿瘤腔和非中央肿瘤位置。

临床怎么用

  • 对于早期乳腺癌患者,省略IMN覆盖可在剂量学上显著降低肩部及胸壁肌肉骨骼结构受量,尤其利于保护后侧肌群。

局限性

  • 本研究为回顾性in silico剂量学分析,样本量较小(30例),需更大规模前瞻性研究验证剂量学获益与放疗后肌肉骨骼副作用的关系。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Breast cancer radiotherapy (RT) can lead to shoulder complications including weakness, restricted motion, and discomfort, affecting up to 40% of patients. The necessity to include the internal mammary nodes (IMNs) during breast and nodal irradiation for every patient remains under discussion, particularly for early-stage breast cancers. The dosimetric effect on nearby musculoskeletal (MSK) structures when targeting the IMNs remains to be completely understood; hence the focus of this current study. METHODS: This retrospective study included breast cancer patients who underwent lumpectomy and nodal sampling followed by adjuvant hypofractionated whole breast and regional nodal RT (4005 cGy in 15 fractions) who were treated between January 1, 2022, and November 30, 2023 at a single institution. MSK structures such as the bones (ribs, scapula), muscles (pectoralis, rhomboids), and joints (glenohumeral, acromioclavicular) were retrospectively contoured on the CT simulation images. Two RT plans (one with and one without IMN coverage) were created, and dosimetric parameters including mean (Dmean), near maximum (D2), near minimum (D98) and volumes received 15, 20 and 40 Gy (V15, V20, V40) were compared. Standardized mean difference between the plans was calculated for each dosimetric parameter, and Wilxocon's signed-rank test was used for comparison. Univariable linear regression analysis was used to identify patient and tumor factors that were associated with more significant dosimetric differences. RESULTS: A total of 30 breast cancer patients with a median age of 63 (range 30-82 years) were selected for analysis. The location of tumours included 15 (50 %) in the right breast, and 15 (50 %) in the left breast; with 10 (33 %) centrally, 10 (33 %) medially, and 10 (33 %) were laterally-located within the breast. The pathologic T stage included 6 (20 %) T0/Tis, 11 (37 %) T1, and 13 (43 %) T2. Seven patients (23 %) were N0, 19 (63 %) were N1, and 4 (13 %) were N2a. Nine patients received adjuvant chemotherapy, 11 neoadjuvant chemotherapy, and 10 patients received no chemotherapy.The exclusion of IMN coverage led to significantly decreased Dmean for muscle groups in the posterior, posterolateral, lateral, anterior and antero-lateral-posterior regions. Specifically, the largest absolute reductions included teres major (Dmean 340 cGy), subscapularis (320 cGy), serratus anterior (241 cGy), latissimus dorsi (232 cGy), chestwall (209 cGy), and the pectoralis minor (37 cGy) muscles. Significant differences were also observed for V40 and V15 of pectoralis minor (V40 of 12 %), pectoralis major (V40 of 10 %), and for both subscapularis and teres major (V15 of 8 %) muscles.Patient factors that were associated with greater dosimetric differences included younger age, larger breast size, larger tumor cavity, and non-central tumor locations. CONCLUSION: This retrospective in silico dosmetric analysis clearly demonstrated that excluding IMN coverage for breast RT significantly reduced the dose received by the MSK structures of the neck, chest wall, and shoulder, particularly in the posterior muscle groups. Future research with larger cohorts and prospective designs would be required to validate these dosimetric benefits and their relationship to MSK-related side effects post-radiotherapy.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Ciocon SL, de la Pena Villarreal A, Lee G, et al. Impact of excluding internal mammary node coverage on musculoskeletal dosimetry in breast radiotherapy. Clin Transl Radiat Oncol. 2025. PMID: 41377100. doi:10.1016/j.ctro.2025.101077

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。